Suppr超能文献

初次观察的非中心累及性糖尿病性黄斑水肿患者的自然病程

Natural course of non-center-involving diabetic macular edema progression in patients under initial observation.

作者信息

Pradhana Divya, Priya N Swathi, Manayath George J, Kulkarni Sucheta, Behera Umesh C, Agarwal Tushar, Agarwal Manisha, Shah Shalin, Giridhar A, Surya Janani, Ramasamy Kim, Vignesh T P, Shoba Sivaprasad, Bhende Muna, Raman Rajiv

机构信息

Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Medical Research Foundation, Chennai, India.

Shri Bhagawan Mahavir Vitreoretinal Services, Vision Research Foundation, Sankara Nethralaya, Chennai, India.

出版信息

Indian J Ophthalmol. 2024 Feb 1;72(2):236-239. doi: 10.4103/IJO.IJO_2182_22. Epub 2023 Dec 26.

Abstract

PURPOSE

We aim to report the natural course of non-center involving diabetic macular edema (NCIDME) progression to center involving diabetic macular edema (CIDME) and associated risk factors.

METHODS

This is a multicenter retrospective comparative study. Data was collected from electronic medical records from 8 centers in India covering. We included patients with type 2 diabetes above 18 years of age with treatment-naïve NCIDME on OCT and best-corrected visual acuity at baseline of 6/12 or better who were under observation for NCIDME and had 2 years follow-up data.

RESULTS

Out of 72 patients with NCIDME, 26.38% patients progressed to CI DME by 2 years, and the visit wise proportion was 11.11% at 6 months, 7% at 1st year and 8.3% at 2 years. The change in CST was statistically significant at 2 years in patients who developed CIDME, the mean difference was 137.73 ± 48.56 microns p = 0.045. Duration of diabetes mellitus > 10 years was the only risk factor for conversion to CIDME.

CONCLUSION

A quarter of eyes with NCIDME developed CIDME and 15% progressed from NPDR to PDR by 2 years, highlighting the disease burden in these patients with NCIDME.

摘要

目的

我们旨在报告非累及黄斑中心凹的糖尿病性黄斑水肿(NCIDME)进展为累及黄斑中心凹的糖尿病性黄斑水肿(CIDME)的自然病程及相关危险因素。

方法

这是一项多中心回顾性对照研究。数据从印度8个中心的电子病历中收集。我们纳入了年龄在18岁以上的2型糖尿病患者,这些患者在OCT检查中初诊为NCIDME,基线最佳矫正视力为6/12或更好,正在接受NCIDME观察且有2年随访数据。

结果

在72例NCIDME患者中,26.38%的患者在2年内进展为CIDME,按就诊时间划分的比例分别为:6个月时为11.11%,1年时为7%,2年时为8.3%。发生CIDME的患者在2年时CST的变化具有统计学意义,平均差值为137.73±48.56微米,p = 0.045。糖尿病病程>10年是转化为CIDME的唯一危险因素。

结论

四分之一的NCIDME患眼发展为CIDME,15%的患者在2年内从非增殖性糖尿病视网膜病变(NPDR)进展为增殖性糖尿病视网膜病变(PDR),突出了这些NCIDME患者的疾病负担。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02ba/10941951/1cccdc3fdcbe/IJO-72-236-g001.jpg

相似文献

1
Natural course of non-center-involving diabetic macular edema progression in patients under initial observation.
Indian J Ophthalmol. 2024 Feb 1;72(2):236-239. doi: 10.4103/IJO.IJO_2182_22. Epub 2023 Dec 26.
2
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
Cochrane Database Syst Rev. 2018 Apr 18;4(4):CD011599. doi: 10.1002/14651858.CD011599.pub2.
4
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD007419. doi: 10.1002/14651858.CD007419.pub5.
5
Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
Cochrane Database Syst Rev. 2023 Jun 27;2023(6):CD007419. doi: 10.1002/14651858.CD007419.pub7.
6
Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.
Cochrane Database Syst Rev. 2011 Jul 6(7):CD008081. doi: 10.1002/14651858.CD008081.pub2.
8
Fenofibrate for diabetic retinopathy.
Cochrane Database Syst Rev. 2023 Jun 13;6(6):CD013318. doi: 10.1002/14651858.CD013318.pub2.
9
Intravitreal steroids for macular edema in diabetes.
Cochrane Database Syst Rev. 2008 Jan 23(1):CD005656. doi: 10.1002/14651858.CD005656.pub2.
10
Aflibercept for neovascular age-related macular degeneration.
Cochrane Database Syst Rev. 2016 Feb 8;2(2):CD011346. doi: 10.1002/14651858.CD011346.pub2.

引用本文的文献

1
Photobiomodulation use in ophthalmology - an overview of translational research from bench to bedside.
Front Ophthalmol (Lausanne). 2024 Aug 15;4:1388602. doi: 10.3389/fopht.2024.1388602. eCollection 2024.
2
The role of real-world studies in the management of non-center-involving diabetic macular edema.
Indian J Ophthalmol. 2024 Feb 1;72(2):289-290. doi: 10.4103/IJO.IJO_1411_23. Epub 2024 Jan 25.

本文引用的文献

4
First-line treatment algorithm and guidelines in center-involving diabetic macular edema.
Eur J Ophthalmol. 2019 Nov;29(6):573-584. doi: 10.1177/1120672119857511. Epub 2019 Jun 26.
9
Topical nepafenec in eyes with noncentral diabetic macular edema.
Retina. 2015 May;35(5):944-56. doi: 10.1097/IAE.0000000000000403.
10
Focal laser photocoagulation in non-center involved diabetic macular edema.
Med Hypothesis Discov Innov Ophthalmol. 2014 Spring;3(1):9-16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验